MicroRNAs in urine are not biomarkers of multiple myeloma
Lenka Sedlaříková, Lenka Bešše, Soňa Novosadová, Veronika Kubaczková, Lenka Radová, Michal Staník, Marta Krejčí, Roman Hájek, Sabina Ševčíková
TL;DR
This study found that microRNAs in urine are not reliable biomarkers for multiple myeloma.
Contribution
The study provides evidence against the use of urine microRNAs as biomarkers for multiple myeloma.
Findings
Twenty microRNAs were found deregulated in urine samples, but most did not reach statistical significance.
Only miR-22-3p showed near-significant differences in expression levels.
The results do not support urine microRNAs as a viable biomarker for multiple myeloma.
Abstract
In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could serve as a biomarker for the disease. Analysis of urine samples was performed using Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) and verified using individual TaqMan miRNA assays for qPCR. We found 20 deregulated microRNA (p < 0.05); for further validation, we chose 8 of them. Nevertheless, only differences in expression levels of miR-22-3p remained close to statistical significance. Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCoffee research and impacts